Bictegravir vs Elvitegravir
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
Bictegravir · Biktarvy
Marketed by Gilead Sciences
NCT02607956 · Phase 3 · completed
This was a randomized, double-blind, active-controlled Phase 3 trial in 657 treatment-naive HIV-1 adults, powered for non-inferiority with a 12% margin. The primary endpoint was the FDA snapshot proportion with HIV-1 RNA <50 copies/mL at Week 48, a clinical virologic endpoint. The pre-specified non-inferiority comparison was met: B/F/TAF 89.4% vs DTG+F/TAF 92.9%, difference -3.5 (95.002% CI -7.9 to 1.0), with the confidence interval entirely within the 12% margin; the superiority test was not significant.
Next expected readout: December 2026 · NCT06830668 (registry estimate)
Reported efficacy
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Participants with HIV-1 RNA ≥50 copies/mL at week 48 (FDA snapshot): 0.4% with B/F/TAF vs 1.1% with dolutegravir plus emtricitabine/tenofovir alafenamide; difference -0.7% (95% CI -2.8% to 1.0%), inside the pre-specified 4% non-inferiority margin (CT.gov posted analysis). (met)
Result source: NCT03110380
Elvitegravir · Stribild
Marketed by Gilead Sciences and partners
NCT01095796 · Phase 3 · completed
Participants were randomized and quadruple-blinded to Stribild or active-controlled Atripla, with 348 and 352 treated participants analyzed, respectively. The primary week-48 virologic endpoint met the prespecified non-inferiority criterion, but HIV-1 RNA suppression is a surrogate endpoint rather than a hard clinical or endoscopic outcome.
Reported efficacy
The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48: The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 (Week 48): Stribild 87.6% vs Atripla 84.1% (met)
Result source: NCT01095796
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Bictegravir | Elvitegravir |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 92.4% vs 93%vs ABC/DTG/3TCNCT026079305 other results
| 87.6% vs 84.1%vs AtriplaNCT0109579634 other results
|
| HIV-1 RNA 50 copies/mL or more (week 48) | 0.4% vs 1.1%vs DTG + F/TAFNCT03110380 | —Not reported |
| CD4 count, change (week 48) | 278 vs 289vs DTG + F/TAFNCT026079566 other results
| 321 vs 300vs AtriplaNCT0109579626 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Bictegravir
- 92.4% vs 93%vs ABC/DTG/3TCNCT02607930
5 other results
- 81.5% vs 84.1% NCT02607930
- 87.9% vs 89.8% NCT02607930
- 93.3% vs 91.1% NCT03110380
- 96.9% vs 93.9% NCT02397694
- 96.9% vs 90.9% NCT02397694
- Elvitegravir
- 87.6% vs 84.1%vs AtriplaNCT01095796
34 other results
- 91.6% vs 88.5% NCT01797445
- 87.2% vs 80.8% NCT01705574
- 93.1% vs 92.8% NCT01780506
- 59% vs 57.8% NCT00708162
- 93.8% vs 87.1% NCT01475838
- 93.4% vs 88.1% NCT01495702
- 89.5% vs 86.8% NCT01106586
- 80.2% vs 75.3% NCT01095796
- 86.9% vs 83.1% NCT01780506
- 77.6% vs 74.6% NCT01106586
- 84.2% vs 81.5% NCT01095796
- 92.8% vs 89.1% NCT01815736
- 84% vs 82.3% NCT01797445
- 89.2% vs 88.2% NCT01780506
- 47.6% vs 45% NCT00708162
- 52.4% vs 53% NCT00708162
- 53.6% vs 56.4% NCT00708162
- 86.9% vs 69.8% NCT01475838
- 86.6% vs 80.4% NCT01495702
- 83.3% vs 82.3% NCT01106586
- 85.9% vs 83.2% NCT01095796
- 88.8% vs 85.5% NCT01095796
- 59.8% vs 57.5% NCT00708162
- 61% vs 60.7% NCT00708162
- 86.1% vs 84.8% NCT01106586
- 91.5% vs 88.5% NCT01106586
- 76.1% vs 78.1% NCT01095796
- 78.4% vs 73.1% NCT01106586
- 88.4% vs 89.7% NCT01497899
- 89.6% vs 87% NCT00869557
- 88.4% vs 87.9% NCT01497899
- 89.6% vs 87% NCT00869557
- 91.7% vs 82.6% NCT00869557
- 89.6% vs 87% NCT00869557
HIV-1 RNA 50 copies/mL or more (week 48)
- Bictegravir
- 0.4% vs 1.1%vs DTG + F/TAFNCT03110380
- Elvitegravir
- —Not reported
CD4 count, change (week 48)
- Bictegravir
- 278 vs 289vs DTG + F/TAFNCT02607956
6 other results
- 299 vs 317 NCT02607930
- 237 vs 281 NCT02607956
- 287 vs 288 NCT02607930
- 180 vs 201 NCT02607956
- 235 vs 228 NCT02607930
- 18 vs 36 NCT03110380
- Elvitegravir
- 321 vs 300vs AtriplaNCT01095796
26 other results
- 323 vs 310 NCT01780506
- 280 vs 293 NCT01106586
- 295 vs 273 NCT01095796
- 360 vs 328 NCT01095796
- 60 vs 42 NCT01815736
- 274 vs 260 NCT01797445
- 285 vs 271 NCT01780506
- 205 vs 198 NCT00708162
- 61 vs 71 NCT01475838
- 83 vs 101 NCT01495702
- 256 vs 261 NCT01106586
- 338 vs 340 NCT01106586
- 239 vs 206 NCT01095796
- 225 vs 200 NCT01797445
- 221 vs 212 NCT01705574
- 235 vs 221 NCT01780506
- 207 vs 211 NCT01106586
- 56 vs -1 NCT02616783
- 138 vs 147 NCT00708162
- 40 vs 32 NCT01475838
- 56 vs 58 NCT01495702
- 48 vs -4 NCT02616783
- 177 vs 204 NCT01497899
- 240 vs 166 NCT00869557
- 165 vs 179 NCT01497899
- 161 vs 117 NCT00869557
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety
Coverage. Bictegravir: 8 of 8 rows · Elvitegravir: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Bictegravir Rows use multiple source trials | Elvitegravir Rows use multiple source trials |
|---|---|---|
| CD4 percent change · % of baseline No placebo or comparator arm | 26.1579% (n=19) @ 48wka,b,c NCT04530630 · Phase 4 · registry result, not featured evidence | 8.1% (n=49) @ 48wka,b,c NCT01721109 · Phase 2/3 · registry result, not featured evidence |
| CD4+ absolute change · cells/uL No placebo or comparator arm | 382.4211 cells/uL @ 48wka,b,c NCT04530630 · Phase 4 · registry result, not featured evidence | 229 cells/uL @ 48wka,b,c NCT01721109 · Phase 2/3 · registry result, not featured evidence |
| Hip BMD percent change · % of baseline Maintenance | -0.802% (n=278) vs -1.148% (n=281) ABC/DTG/3TC @ 48wkb,c NCT02607930 · Phase 3 · HIV · phase 3 | 1.33% (n=101) vs -0.726% (n=54) Stay on Baseline Regimen @ 48wkb,c NCT02616783 · Phase 3 · registry result, not featured evidence |
| HIV-1 RNA absolute change · log Maintenance | -3.08 vs -3.1 DTG + F/TAF log @ 96wkd,c NCT02607956 · Phase 3 · HIV · phase 3 1 other source trial-3.09 vs -3.1 ABC/DTG/3TC log @ 96wk NCT02607930 · Phase 3 · HIV · phase 3 | -2.26 vs -2.31 Raltegravir log @ 96wkd,c NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 |
| Dropout rate | 18.7%e NCT02607956 · Phase 3 · HIV · phase 3 show 15 more results17.1%B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 —B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 7.4%B/F/TAF NCT03110380 · Phase 3 —Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · combination 5% NCT04530630 · Phase 4 · registry result, not featured evidence 11.9% NCT05405751 · Phase 4 · registry result, not featured evidence — NCT03656783 · Phase 3 · registry result, not featured evidence 4.6%BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination —BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination 20%50 mg NCT02275065 · Phase 1 · registry result, not featured evidence 20%100 mg NCT02275065 · Phase 1 · registry result, not featured evidence 0%25 mg NCT02275065 · Phase 1 · registry result, not featured evidence 20%5 mg NCT02275065 · Phase 1 · registry result, not featured evidence | 83.6%f NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 38 more results22.2% NCT02477527 · Phase 4 · registry result, not featured evidence —DSG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 6.3%Delayed Switch Group (DSG) NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 0-24 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 5.1%Immediate Switch Group (ISG) NCT02397096 · Phase 3 · registry result, not featured evidence 5.1%E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 · registry result, not featured evidence —Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence 20%E/C/F/TAF NCT01797445 · Phase 3 · registry result, not featured evidence —E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 · registry result, not featured evidence —DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence —Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 5.4% NCT02616783 · Phase 3 · registry result, not featured evidence —Double-Blind: E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 16%E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —Open-Label: E/C/F/TAF to E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 43.2% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 12.3%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 12.1%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 10.2% NCT01475838 · Phase 3 · registry result, not featured evidence —All Stribild NCT01495702 · Phase 3 · registry result, not featured evidence 8.9%Stribild NCT01495702 · Phase 3 · registry result, not featured evidence —Stribild (Randomized Phase) NCT01495702 · Phase 3 · registry result, not featured evidence 80.7% NCT01106586 · Phase 3 · registry result, not featured evidence 0% NCT01533259 · Phase 3 · registry result, not featured evidence 14% NCT01721109 · Phase 2/3 · registry result, not featured evidence 5.3% NCT01497899 · Phase 2 · registry result, not featured evidence 6.3% NCT00869557 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 1.2%e NCT02607956 · Phase 3 · HIV · phase 3 show 15 more results0%B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 —B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 1.1%B/F/TAF NCT03110380 · Phase 3 —Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · combination — NCT04530630 · Phase 4 · registry result, not featured evidence — NCT05405751 · Phase 4 · registry result, not featured evidence — NCT03656783 · Phase 3 · registry result, not featured evidence 1.5%BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination —BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination —50 mg NCT02275065 · Phase 1 · registry result, not featured evidence —100 mg NCT02275065 · Phase 1 · registry result, not featured evidence —25 mg NCT02275065 · Phase 1 · registry result, not featured evidence —5 mg NCT02275065 · Phase 1 · registry result, not featured evidence | 2.5%f NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 38 more results— NCT02477527 · Phase 4 · registry result, not featured evidence —DSG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 0.4%Delayed Switch Group (DSG) NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 0-24 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 1.6%Immediate Switch Group (ISG) NCT02397096 · Phase 3 · registry result, not featured evidence 0.7%E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 · registry result, not featured evidence —Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence 0.7%E/C/F/TAF NCT01797445 · Phase 3 · registry result, not featured evidence —E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 · registry result, not featured evidence —DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence —Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 0.9% NCT02616783 · Phase 3 · registry result, not featured evidence —Double-Blind: E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0.9%E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —Open-Label: E/C/F/TAF to E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 2.2% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 4.1%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 6.1%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 2% NCT01475838 · Phase 3 · registry result, not featured evidence —All Stribild NCT01495702 · Phase 3 · registry result, not featured evidence 0.7%Stribild NCT01495702 · Phase 3 · registry result, not featured evidence —Stribild (Randomized Phase) NCT01495702 · Phase 3 · registry result, not featured evidence 2.5% NCT01106586 · Phase 3 · registry result, not featured evidence — NCT01533259 · Phase 3 · registry result, not featured evidence — NCT01721109 · Phase 2/3 · registry result, not featured evidence 0.9% NCT01497899 · Phase 2 · registry result, not featured evidence — NCT00869557 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 20%e NCT02607956 · Phase 3 · HIV · phase 3 show 15 more results14%B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 7.5%B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · HIV · phase 3 —B/F/TAF NCT03110380 · Phase 3 12.7%Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 9.6%Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 9.5%Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · combination 5% NCT04530630 · Phase 4 · registry result, not featured evidence 4% NCT05405751 · Phase 4 · registry result, not featured evidence 0% NCT03656783 · Phase 3 · registry result, not featured evidence —BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination 6.2%BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination 0%50 mg NCT02275065 · Phase 1 · registry result, not featured evidence 0%100 mg NCT02275065 · Phase 1 · registry result, not featured evidence 0%25 mg NCT02275065 · Phase 1 · registry result, not featured evidence 0%5 mg NCT02275065 · Phase 1 · registry result, not featured evidence | 19.8%f NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 38 more results0% NCT02477527 · Phase 4 · registry result, not featured evidence 1.9%DSG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence 6.4%DSG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence 4.5%DSG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence 2.3%DSG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence —Delayed Switch Group (DSG) NCT02397096 · Phase 3 · registry result, not featured evidence 2.9%ISG Base Study Weeks 0-24 NCT02397096 · Phase 3 · registry result, not featured evidence 2.6%ISG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence 9.3%ISG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence 4.3%ISG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence 3.6%ISG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence —Immediate Switch Group (ISG) NCT02397096 · Phase 3 · registry result, not featured evidence —E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence 3%Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 · registry result, not featured evidence 5.2%Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 · registry result, not featured evidence 8.2%Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence —E/C/F/TAF NCT01797445 · Phase 3 · registry result, not featured evidence 12.5%E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 · registry result, not featured evidence 2.8%Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 · registry result, not featured evidence 1.7%Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 · registry result, not featured evidence 5.3%DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence 8.7%Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 9.1% NCT02616783 · Phase 3 · registry result, not featured evidence 16.8%Double-Blind: E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0%Open-Label: E/C/F/TAF to E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 20.6% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 15.1%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 18.2%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 8.2% NCT01475838 · Phase 3 · registry result, not featured evidence 8.9%All Stribild NCT01495702 · Phase 3 · registry result, not featured evidence —Stribild NCT01495702 · Phase 3 · registry result, not featured evidence 8.2%Stribild (Randomized Phase) NCT01495702 · Phase 3 · registry result, not featured evidence 16.4% NCT01106586 · Phase 3 · registry result, not featured evidence 2.1% NCT01533259 · Phase 3 · registry result, not featured evidence 10% NCT01721109 · Phase 2/3 · registry result, not featured evidence 10.7% NCT01497899 · Phase 2 · registry result, not featured evidence 4.2% NCT00869557 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 12 more resultsdiarrhoea 17.2% upper respiratory tract infection 14.6% headache 14% NCT02607930 · Phase 3 · HIV · phase 3 loose stool/ diarrhea 25% NCT04530630 · Phase 4 · registry result, not featured evidence shortness of breath 8% NCT03656783 · Phase 3 · registry result, not featured evidence diarrhoea 13.8% upper respiratory tract infection 10.8% headache 9.2% NCT02397694 · Phase 2 · registry result, not featured evidence · combination 50 mg fatigue 25% (placebo 0%) papule 25% (placebo 0%) arthropod bite 0% (placebo 0%) NCT02275065 · Phase 1 · registry result, not featured evidence 100 mg arthropod bite 25% (placebo 0%) diarrhoea 25% (placebo 0%) headache 25% (placebo 25%) NCT02275065 · Phase 1 · registry result, not featured evidence 25 mg headache 25% (placebo 25%) arthropod bite 0% (placebo 0%) blood creatine phosphokinase increased 0% (placebo 0%) NCT02275065 · Phase 1 · registry result, not featured evidence 5 mg blood creatine phosphokinase increased 25% (placebo 0%) diarrhoea 25% (placebo 0%) headache 25% (placebo 25%) NCT02275065 · Phase 1 · registry result, not featured evidence | f diarrhoea 26.7% upper respiratory tract infection 26.4% nausea 23% NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 31 more resultsheadache 6.7% diarrhoea 4.3% nasopharyngitis 4.3% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 14.4% headache 6.4% diarrhoea 5.4% NCT02397096 · Phase 3 · registry result, not featured evidence covid-19 3.9% headache 1.9% back pain 1.3% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.4% headache 6.5% diarrhoea 4.5% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.4% back pain 3.7% diarrhoea 3% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 12.8% headache 5.5% arthralgia 5.3% NCT02397096 · Phase 3 · registry result, not featured evidence back pain 2.3% arthralgia 1.7% nasopharyngitis 1.7% NCT02397096 · Phase 3 · registry result, not featured evidence covid-19 8.3% arthralgia 1.2% diarrhoea 1.2% NCT02397096 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 7.4% nasopharyngitis 5.2% diarrhoea 4.4% NCT01815736 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 6.1% diarrhoea 5.2% nasopharyngitis 4.7% NCT01815736 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.5% diarrhoea 11.4% nasopharyngitis 10% NCT01815736 · Phase 3 · registry result, not featured evidence diarrhoea 23% headache 22.7% upper respiratory tract infection 20.2% NCT01797445 · Phase 3 · registry result, not featured evidence nasopharyngitis 3.5% headache 2.8% arthralgia 1.4% NCT01797445 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.2% cough 2.5% syphilis 2.5% NCT01797445 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 14.6% headache 11% anaemia 7.3% NCT01705574 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.3% headache 17% nausea 14.9% NCT01705574 · Phase 3 · registry result, not featured evidence nasopharyngitis 10.9% back pain 8.2% diarrhoea 7.3% NCT02616783 · Phase 3 · registry result, not featured evidence diarrhoea 25.7% upper respiratory tract infection 21.1% nausea 16.8% NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 cough 4.4% syphilis 4.4% upper respiratory tract infection 3.3% NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 diarrhoea 33.9% upper respiratory tract infection 21.2% headache 13.8% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 upper respiratory tract infection 20.5% nasopharyngitis 19.2% bronchitis 13.7% NCT01363011 · Phase 3 · registry result, not featured evidence · combination diarrhoea 36.4% insomnia 21.2% headache 18.2% NCT01363011 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 13.3% upper respiratory tract infection 9.9% diarrhoea 9.2% NCT01475838 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 11.3% diarrhoea 10.2% nasopharyngitis 10.2% NCT01495702 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 11.3% diarrhoea 10.3% nasopharyngitis 10.3% NCT01495702 · Phase 3 · registry result, not featured evidence diarrhoea 28% upper respiratory tract infection 24.4% nausea 22.7% NCT01106586 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 20.8% insomnia 12.5% anxiety 10.4% NCT01533259 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 36% headache 24% vomiting 20% NCT01721109 · Phase 2/3 · registry result, not featured evidence nausea 22.3% diarrhoea 17% fatigue 16.1% NCT01497899 · Phase 2 · registry result, not featured evidence diarrhoea 27.1% fatigue 16.7% headache 14.6% NCT00869557 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 4 versus Phase 2/3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dPopulation context differs: baseline_threshold differs (hiv_viral_load>=500 versus hiv_viral_load>=1000); prior_therapy differs (naive versus experienced).
- ePopulation comparability has not been reviewed for 13 of these studies.
- fPopulation comparability has not been reviewed for 34 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Bictegravir
show 2 more results
show 5 more results
show 2 more results
show 2 more results
Elvitegravir
show 3 more results
show 1 more result
show 1 more result
show 3 more results
show 3 more results
show 1 more result
show 5 more results
show 11 more results
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bictegravir's landscape · Elvitegravir's landscape